All In Biotech

Drug Trial Radar · NCT07893444

BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children

A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of a Short-Course Treatment Regimen for Non-Severe Pulmonary Tuberculosis in Children (BRIGHT-Child TB)

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 8, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Huashan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis. The main questions it aims to answer are: * Do the 3-month bedaquiline, delamanid, contezolid, and pyrazinamide regimen (BDCZ) and the 4-month fixed-dose combination (FDC) regimen provide effective treatment, as measured by tuberculosis-free survival at 12 months after treatment initiation? * What are the safety profiles of the two short-course regimens, as measured by the incidence of grade 3 or higher adverse events? * How do the short-course regimens compare with the standard 6-month treatment regimen in terms of treatment success, treatment failure, recurrence, and tuberculosis-free survival during follow-up? Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis. Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.

Conditions

  • Tuberculosis

Interventions

  • 4-month FDC-based regimenDrug

    4-month fixed-dose combination (FDC) regimen

  • 3-month BDCZ regimenDrug

    3-month bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ) regimen

  • Standard 6-month treatment regimenDrug

    Standard 6-month treatment regimen, namely 2HRZ(E)/HR.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tuberculosis-free survival at 12 monthsTime frame: 12 months after treatment initiation
  2. Incidence of grade 3 or higher adverse eventsTime frame: From treatment initiation to the end of the assigned treatment regimen (3, 4, or 6 months)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province

    Fuzhou, Fujian, China · Recruiting

  • Guangzhou Chest Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Guiyang Public Health Clinical Center

    Guiyang, Guizhou, China · Recruiting

  • Third People's Hospital of Liupanshui

    Liupanshui, Guizhou, China · Recruiting

  • Zunyi Infectious Diseases Hospital

    Zunyi, Guizhou, China · Recruiting

  • The Fifth People's Hospital of Suzhou

    Suzhou, Jiangsu, China · Recruiting

  • Ganzhou Fifth People's Hospital

    Ganzhou, Jiangxi, China · Recruiting

  • The Fourth People's Hospital of Qinghai Province

    Xining, Qinghai, China · Recruiting

  • Shandong Public Health Clinical Center

    Jinan, Shandong, China · Recruiting

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of Shihezi University

    Shihezi, Xinjiang Uygur Autonomous Region, China · Recruiting

  • Hangzhou Red Cross Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.